Apotransferrin in Patients With β-thalassemia

Summary

The aim of the trial is to study the effect of apotransferrin administration in patients suffering from β-thalassemia intermedia in order to restore the erythropoiesis as reflected by enhanced haemoglobin levels or reduced transfusion dependency.

Timeline

Start

2019-03-21

Primary completion

2022-03-31

Completion

2022-03-31

Outcome

Outcome not reported

Stopped: “no availability of IMP for this study”

Drugs

Indications